A Hyperleukocytosis In Patients With Lung Cancer


  • Divian Ozaza Sari Universitas Lampung
  • Yusuf Aulia Rahman Bagian Ilmu Penyakit Dalam, Rumah Sakit Abdoel Moloek Lampung




Hiperleukositosis, kanker paru


Leukocytosis can be found in patients with lung cancer at the time of diagnosis or during the course of the disease. Hyperleukocytosis was defined as a leukocyte count above 11.000/mL on pheripheral blood. This case report describes hyperleukocytosis in a paraneoplastic syndrome resulting from lung cancer in a 42-year-old man who has had fever and weakness since the last 3 months. Peripheral blood morphological examination, there is increased leukocyte, 88% segment neutrophils, no blast cell and negative BCR-ABL examination. In people with lung cancer, leukocytosis can be caused by infection, use of corticosteroid,  hematopoietic disorders, bone marrow involvement, or paraneoplastic manifestations. Paraneoplastic leukocytosis is associated with poor prognosis and aggressive disease, so the diagnosis of hyperleukocytosis in paraneoplastic syndromes is important because it determines the patient's prognosis. Paraneoplastic syndrome is a symptom seen in certain malignancies and is not associated with direct cancer invasion and occurs in 7-15% of all patients with cancer. Solid tumors activate a variety of different systems, namely the endocrine, neurological, mucocutaneous, and hematological systems. Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), Granulocyte Colony Stimulating Factor (G-CSF), interleukin (IL) -1, IL-6 and Tumor Necrosis Factor (TNF)-α have been implicated in paraneoplastic leukemoid reactions. Among these, G-CSF is the strongest cytokine that triggers hyperleukocytosis.


Riley LK, Rupert J. Evaluation of Patients with Leukocytosis. Am Fam Physician. 2015;92(11):1004-11. [PubMed]

Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246–3252.

Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin. Oncol. 1992 Feb;19(1):47-84. [PubMed]

Cerny J, Rosmarin AG. Why does my patient have leukocytosis? Hematol Oncol Clin North Am. 2012;26(2): 303-319, viii.

Kiladjian JJ. The Spectrum of JAK2-Positive Myeloproliferative Neoplasms. Hematology American Society of Hematology Education Program. 2012; 561-6.

Spivak JL and Silver RT. The Revised World Health Organization Diagnostic Criteria for Polycythemia Vera, Essential Thrombocytosis, and Primary Myelofibrosis: an Alternative Proposal. Blood. 2008; 112: 231-9.

Latif N, Guthrie T and Rana F. JAK2 Gene Mutation: Impact on Pathogenesis, Classification, and Management of Myeloproliferative Neoplasms. 2010, p.109–14.

Buyukasik Y, Haznedaroglu IC, Ilhan O. Chronic myeloid leukemia: Practical issues in diagnosis, treatment, and follow up. Int J Hematol Oncol. 2010;20(2 Suppl 1):1-12.

American Cancer Society. Cancer Facts & Figures 2019. Atlanta: American Cancer Society; 2019.

Jabbour E, Cortes JE, Kantarjian HM. Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications. Cancer. 2008; 112(10): 2112‐ 2118.

Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR‐ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008; 111(4): 1774‐ 1780.

Schoch C, Schnittger S, Bursch S, et al. Comparison of chromosome banding analysis, interphase‐ and hypermetaphase‐FISH, qualitative and quantitative PCR for diagnosis and for follow‐up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002; 16: 53.

Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson CL et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, adn prognostic relevance. American J Haematol. 2013;88(3):201-206.

Bakta IM. Hematologi klinik ringkas. EGC. 2015;178-185.

Patnaik MM, Tefferi A. Chronic Myelomonocytic Leukemia: Update on Diagnosis, Risk Stratification, and Management. American J Haematol. 2018;93(6):824-840

Benton CB, Nazha A, Pemmaraju N, GarciaManero G. Chronic myelomonocytic leukemia. Crit rev oncol haematol. 2015;95(2):222-242.

Maxson JE, Gotlib J, Pollyea DA, et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med. 2013;368(19):1781–1790.

Pardanani A, Lasho TL, Laborde RR, et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013;27(9):1870–1873.

Vardiman J, Hyjek E. World health organization classification, evaluation, and genetics of the myeloproliferative neoplasm variants. Hematology 2011; 2011: 250-6.

Elliott MA, Hanson CA, Dewald GW, Smoley SA, Lasho TL, Tefferi A. WHO-defined chronic neutrophilic leukemia: A long-term analysis of 12 cases and a critical review of the literature. Leukemia 2005; 19: 313-7.

Reilly JT. Chronic neutrophilic leukaemia: a distinct clinical entity? Br J Haematol 2002; 116: 10-8.

Tefferi A. JAK2 Mutations and Clinical Practice in Myeloproliferative Neoplasms. Cancer J 2007; 13: 366-71.

Baxter EJ, Scott LM, Campbell PJ. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders (vol 365, pg 1054, 2005). Lancet 2005; 366: 122.

Auche, M. Des nevritesperipheriques chez les cancereux. (1890) Rev Med (Paris) 10: 785-807. PubMed│CrossRef│Others

Chabot-Richards, D.S., George, T.I. Leukocytosis. (2014) Int J Lab Hematol 36(3):279-288. PubMed│CrossRef│Others

Sakka V, Tsiodras, S., Giamarellos-Bourboulis, E.J., et al. An update on the etiology and diagnostic evaluation of a leukemoid reaction. (2006) Eur J Intern Med 17(6): 394–398.PubMed│CrossRef│Others

Kasuga I, Makino S, Kiyokawa H, Katoh H, Ebihara Y, Ohyashiki K. Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma. Cancer 2001;92:2399-405.

Richardson GE, Johnson BE. Paraneoplastic syndromes in lung cancer. Curr Opin Oncol 1992;4:323-33.

Ascensao, J.L., Oken, M.M., Ewing, S.L., et al. Leukocytosis and large cell lung cancer. A frequent association. (1987) Cancer 60(4): 903-905. PubMed│CrossRef│Others

Sato, K., Fujii, Y., Ono, M., et al. Production of interleukin 1α-like factor and colony-stimulating factor by a squamous cell carcinoma of the thyroid (T3M-5) derived from a patient with hypercalcemia and leukocytosis. (1987) Cancer Res 47(24 Pt 1): 6474-6480. PubMed│CrossRef│Others

Black, K., Garrett, I.R., Mundy, G.R. Chinese Hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis, and thrombocytosis in tumor bearing nude mice.Endocrinology.1991;128(5): 2657-2659. PubMed│CrossRef│Others

Yoneda, T., Alsina, M.A., Bonewald, L., et al. Evidence that tumor necrosis factor plays a pathogenic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in a nude mice. (1991) J Clin Invest 87(3): 977-985. PubMed│CrossRef│Others

Myers TJ, Cole SR, Klatsky AU, et al. Respiratory failure due to pulmonary leukostasis following chemotherapy of acute non-lymphocytic leukemia. Cancer. 1983;53:1808–1813.

Dombret H, Hunault M, Faucher C, et al. Acute lysis pneumopathy after chemotherapy for acute myelomonocytic leukemia with abnormal marrow eosinophils. Cancer. 1992;69:1356–1361.

Tryka AF, Godleski JJ, Fanta CH. Leukemic cell lysis pneumopathy after chemotherapy: a complication of treated myeloblastic leukemia. Cancer. 1982;50:2763–2770.

Grund FM, Armitage JO, Burns CP. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Int Med. 1977;137:1246–1247.

Porcu P, Farag S, Marcucci G, et al. Leukocytoreduction for acute. Leukemia Ther Apher. 2002;6(1):15–23.

Porcu P, Danielson CF, Orazi A, et al. Therapeutic leukapheresis in hyperleukocytosis leukaemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol. 1997;98:433–436.

Hölig K, Moog R. Leukocyte depletion by therapeutic leukocytapheresis in patients with leukemia. Transfus Med Hemother. 2012;39(4):241–245.



How to Cite

Sari, D. O., & Yusuf Aulia Rahman. (2021). A Hyperleukocytosis In Patients With Lung Cancer. Medical Profession Journal of Lampung, 10(4), 760-766. https://doi.org/10.53089/medula.v10i4.136